Skip to main content

Q&A for Upcoming ISEH Journal Club

The New Investigators Committee is excited to announce the second ISEH Journal Club, which will run next week (24 - 28 April). We'll be discussing a recent paper in EMBO entitled Osteopontin attenuates aging‐associated phenotypes of hematopoietic stem cells with the paper's first author, Novella Guidi.  Starting 24 April, you can ask Novella any questions about the paper through the ISEH Facebook group

As before, to help introduce this paper and start the discussion, we conducted a Q&A with Novella. This recent publication came from her PhD research with Dr. Hartmut Geiger at the University of Ulm. Novella is currently a postdoctoral fellow with Dr. Valter Longo at the University of Southern California.

What was the motivation for studying hematopoietic stem cell aging?
What motivates me and the laboratory about studying the aging of hematopoietic stem cell (HSC) is that aging at the stem cell level is one underlying cause of aging-associated immune-senescence as well as leukemia. In fact upon aging HSCs undergo changes in function and structure, including skewing to myeloid lineages, lower reconstitution potential and loss of protein polarity, which influences health span. What is highly exciting about studying HSC aging is that the functional decline of aged stem cells may be reversible and that rational interventions to achieve HSC rejuvenation can be developed by targeting HSC aging mechanisms, thereby allowing for a more healthy aging.

What are the key findings of your paper?
The first important finding in the paper is that an aged-related decline of osteopontin (OPN) in the bone marrow niche microenvironment is able to extrinsically result in HSC aging, while so far mainly HSC intrinsic mechanisms have been considered to be the important driving force of the aging process. Secondly, exposure of aged HSCs to activated OPN fragments attenuated aging of old HSCs, resulting in increased engraftment, decreased HSC frequency, increased stem cell polarity and a restored balance of lymphoid and myeloid cells in blood. This nicely demonstrates how rescuing  osteopontin levels in the niche supports a more youthful HSC function.


How do you think your story will impact the blood field? What do you see as the important next steps?
I think our findings emphasize the importance and the contribution of the niche microenvironment in driving or exacerbating HSC phenotypes, and especially being considered when rejuvenation therapies are being established. Our study in fact points to exciting novel ways to improved immune system in old individuals and possibly reduction of oncogenic transformation upon aging, by therapeutically targeting the place where blood stem cells reside. Interestingly, osteopontin levels are not only low in the bone marrow niche, but also in the peripheral blood upon aging therefore as a next step we are aiming to use osteopontin replacement therapy in mice to reverse the influence of an aging niche. Our findings cannot at this stage be directly extended to clinical treatment of human patients, but the data provide interesting leads that one day could benefit human health by boosting the immune system of elderly people.

Are there members of our ISEH community that contributed to the context for your paper? How did he/she contribute to your research question?
Yes, there are few people of the ISEH community that contributed to my project development path. Most of all it was the work previously done by Dr. Susie Nilsson that inspired me in digging deeper into the osteopontin signaling pathway upon niche aging. In fact, she previously showed that OPN knock-out mice had an increased HSC pool size in vivo with markedly enhanced cycling, suggesting osteopontin as a key regulator of HSC quiescence. Moreover, work from Dr. Peggy Goodell showed how aged circulatory factors and the bone marrow cytokine RANTES are able to influence the HSC myeloid skewing phenotype and that heterochronic transplants of aged HSCs into young animal generate less myeloid cells. Altogether their data implied a critical role of a young and functional niche in supporting young and healthy HSCs and immune cell production, which directly inspired me to investigate the role of osteopontin in influencing HSC aging-related phenotypes.

Who would you particularly like to read your paper?
If I have to think about someone I would particularly like to read my paper this person would be Dr. Paul Frenette. His excellent work on unraveling the nature and function of the HSC niche microenvironment has always fascinated me. He elegantly demonstrated, based on distinct genetic mouse model and advanced high resolution imaging, that the perivascular area of the sinusoidal blood vessels is the region in which HSC mostly resides, surrounded by important niche cell types that further regulate HSC function and maintenance. The endosteal niche is highly vascularized, implying that the cellular components of the niche that regulate HSC function are interconnected. During the past years’ conferences, I got the chance to meet him a couple of times and I always loved discussing my data and findings with him. His critical point of view always inspired me to view, analyze and interpret my results critically. These conversations gave me the confidence that I was digging in the right direction. I would like him to read my paper because I am sure he would be highly critical by asking a lot of tricky questions, while he would have of course additional advice for the next steps in my research endeavor.


Thank you to Novella Guidi for participating in our 2017 ISEH Journal Club.  Please visit the ISEH Facebook group from 24 - 28 April to submit your questions and join the discussion.



Novella Guidi, PhD
ISEH New Investigators Committee Member

Postdoctoral Fellow
University of Southern California / Leonard Davis School of Gerontology

Comments

  1. Q and A is the most appropriate method to conduct an interview and to also get the intended information from an audience thanks for sharing this keep up the good job

    ReplyDelete

Post a Comment

Popular posts from this blog

How to Make the Most Out of Your Lab’s Move

“The lab is moving!” I must confess, when I heard these words from my mentor about a year and a half ago, my heart dropped. Lab relocation experiences are some of the worst horror stories that you hear from fellow researchers: precious samples lost, mouse colonies never recovered, months spent re-establishing protocols. Moreover, it also meant I would have to leave San Francisco, a beautiful city that I loved to live in, and where I found many friends. Being a scientist often means not having much choice of geographic location of your work. The choice of a particular subject or even broad field usually requires a move to a new city, or even a new country. Moving with the lab means making this choice again – do I leave my project and all the progress behind, or do I accept the delay in my research and go ahead. Now, two months after our move to New York, I would like to reflect on my experiences and that of my fellow lab members on our cross-country relocation from the trainee perspect…

The cost of a postdoctoral experience and its impact on STEM diversity

Academic diversity in the biological sciences isn't what it should be.  At the most basic level, representation by underrepresented groups in the top research universities in the United States is less than 5%1.  Despite gains in enrollment of underrepresented students in the biological sciences at the undergraduate and doctoral levels, these gains do not extend to the tenure-track realm, where representation has changed very little over the past three decades. 

At another level, because of the ferocious degree of competition in science today - for publication in high impact journals, for limited grant funds, for fewer tenure-track positions -- one might argue that academic diversity is slowly been shaped by a "1%" mindset.  Perhaps more than ever before, the institution you come from-- even the lab you come from-- influences where you will publish, whether you will attain funding, and ultimately whether you will succeed. My purpose here is not to grumble; I'm sure th…

When people can…

As long as I can remember, there were people marching on the streets, either protesting or celebrating or even supporting the topic of the manifestation. It always fascinated me how powerful people can be, when they come together. In cases of manipulation of the public opinion this is of course not good. However, many times this can influence things in a positive way. Coming from a country like Greece, I have to admit that it was fairly frequent for me to see people getting together on the streets for a variety of reasons. Then, when I moved myself and my life to Boston, these events happened less frequently. I remember that I joined a protest in Boston once (although maybe this is not the right time to admit such a thing). It was about the Gulf war and people wanting their children to come back home. The subject of the protest was noble, however only a few people participated. Thus, it was to my great surprise and satisfaction when on April 22nd, 2017 the March for Science was organi…